QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   243.02 (-2.07%)
META   147.71 (-2.66%)
GOOGL   97.14 (-2.24%)
AMZN   100.56 (-1.64%)
TSLA   168.10 (-5.51%)
NVDA   192.77 (-5.34%)
NIO   12.03 (-5.35%)
BABA   111.46 (-5.85%)
AMD   72.53 (-3.81%)
T   20.18 (+1.15%)
MU   62.01 (-2.91%)
F   12.93 (-2.56%)
CGC   2.84 (-3.07%)
GE   81.09 (-2.57%)
DIS   107.98 (-1.42%)
AMC   5.07 (-7.99%)
PFE   43.58 (-0.48%)
PYPL   80.22 (-1.97%)
NFLX   354.06 (-1.86%)
QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   243.02 (-2.07%)
META   147.71 (-2.66%)
GOOGL   97.14 (-2.24%)
AMZN   100.56 (-1.64%)
TSLA   168.10 (-5.51%)
NVDA   192.77 (-5.34%)
NIO   12.03 (-5.35%)
BABA   111.46 (-5.85%)
AMD   72.53 (-3.81%)
T   20.18 (+1.15%)
MU   62.01 (-2.91%)
F   12.93 (-2.56%)
CGC   2.84 (-3.07%)
GE   81.09 (-2.57%)
DIS   107.98 (-1.42%)
AMC   5.07 (-7.99%)
PFE   43.58 (-0.48%)
PYPL   80.22 (-1.97%)
NFLX   354.06 (-1.86%)
QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   243.02 (-2.07%)
META   147.71 (-2.66%)
GOOGL   97.14 (-2.24%)
AMZN   100.56 (-1.64%)
TSLA   168.10 (-5.51%)
NVDA   192.77 (-5.34%)
NIO   12.03 (-5.35%)
BABA   111.46 (-5.85%)
AMD   72.53 (-3.81%)
T   20.18 (+1.15%)
MU   62.01 (-2.91%)
F   12.93 (-2.56%)
CGC   2.84 (-3.07%)
GE   81.09 (-2.57%)
DIS   107.98 (-1.42%)
AMC   5.07 (-7.99%)
PFE   43.58 (-0.48%)
PYPL   80.22 (-1.97%)
NFLX   354.06 (-1.86%)
QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   243.02 (-2.07%)
META   147.71 (-2.66%)
GOOGL   97.14 (-2.24%)
AMZN   100.56 (-1.64%)
TSLA   168.10 (-5.51%)
NVDA   192.77 (-5.34%)
NIO   12.03 (-5.35%)
BABA   111.46 (-5.85%)
AMD   72.53 (-3.81%)
T   20.18 (+1.15%)
MU   62.01 (-2.91%)
F   12.93 (-2.56%)
CGC   2.84 (-3.07%)
GE   81.09 (-2.57%)
DIS   107.98 (-1.42%)
AMC   5.07 (-7.99%)
PFE   43.58 (-0.48%)
PYPL   80.22 (-1.97%)
NFLX   354.06 (-1.86%)

Vanda Pharmaceuticals - VNDA Stock Forecast, Price & News

$7.61
-0.04 (-0.52%)
(As of 01/30/2023 03:49 PM ET)
Add
Compare
Today's Range
$7.51
$7.64
50-Day Range
$6.87
$10.96
52-Week Range
$6.73
$15.23
Volume
172,124 shs
Average Volume
530,817 shs
Market Capitalization
$430.65 million
P/E Ratio
63.42
Dividend Yield
N/A
Price Target
$12.00

Vanda Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
58.5% Upside
$12.00 Price Target
Short Interest
Healthy
3.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
1.62mentions of Vanda Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$612,966 Sold Last Quarter
Proj. Earnings Growth
860.00%
From $0.05 to $0.48 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.99 out of 5 stars

Medical Sector

13th out of 1,049 stocks

Pharmaceutical Preparations Industry

6th out of 514 stocks


VNDA stock logo

About Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
Should Value Investors Buy Exelixis (EXEL) Stock?
See More Headlines
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Company Calendar

Last Earnings
11/02/2022
Today
1/30/2023
Next Earnings (Estimated)
2/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VNDA
CUSIP
92165910
Employees
278
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+57.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$33.15 million
Pretax Margin
3.99%

Debt

Sales & Book Value

Annual Sales
$268.68 million
Cash Flow
$0.67 per share
Book Value
$9.06 per share

Miscellaneous

Free Float
52,629,000
Market Cap
$430.65 million
Optionable
Optionable
Beta
0.64

Social Links


Key Executives

  • Dr. Mihael H. Polymeropoulos M.D. (Age 63)
    Founder, Pres, CEO & Chairman of The Board
    Comp: $1.4M
  • Mr. Kevin Patrick Moran (Age 39)
    Sr. VP, CFO & Treasurer
    Comp: $615.51k
  • Mr. Timothy Williams (Age 47)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $675.67k
  • Mr. Joakim WijkstromMr. Joakim Wijkstrom (Age 57)
    Sr. VP & Chief Marketing Officer
    Comp: $779.67k
  • Mr. Gunther Birznieks (Age 53)
    Sr. VP of Bus. Devel.
    Comp: $644.4k
  • Mr. Scott L. Howell
    Chief People Officer
  • Ms. Elizabeth Van Every
    Head of Corp. Affairs













VNDA Stock - Frequently Asked Questions

Should I buy or sell Vanda Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VNDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VNDA, but not buy additional shares or sell existing shares.
View VNDA analyst ratings
or view top-rated stocks.

What is Vanda Pharmaceuticals' stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year price objectives for Vanda Pharmaceuticals' shares. Their VNDA share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's share price to reach $12.00 in the next year. This suggests a possible upside of 56.9% from the stock's current price.
View analysts price targets for VNDA
or view top-rated stocks among Wall Street analysts.

How have VNDA shares performed in 2023?

Vanda Pharmaceuticals' stock was trading at $7.39 on January 1st, 2023. Since then, VNDA shares have increased by 3.5% and is now trading at $7.65.
View the best growth stocks for 2023 here
.

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our VNDA earnings forecast
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, November, 2nd. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by $0.04. The biopharmaceutical company had revenue of $65.32 million for the quarter, compared to analysts' expectations of $71 million. Vanda Pharmaceuticals had a net margin of 2.52% and a trailing twelve-month return on equity of 1.28%.

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $240.00 million-$270.00 million, compared to the consensus revenue estimate of $273.80 million.

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (2.81%), Allspring Global Investments Holdings LLC (0.41%), Exchange Traded Concepts LLC (0.10%), Strs Ohio (0.09%), Yousif Capital Management LLC (0.06%) and Comerica Bank (0.06%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams.
View institutional ownership trends
.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $7.65.

How much money does Vanda Pharmaceuticals make?

Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $432.91 million and generates $268.68 million in revenue each year. The biopharmaceutical company earns $33.15 million in net income (profit) each year or $0.12 on an earnings per share basis.

How many employees does Vanda Pharmaceuticals have?

The company employs 278 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450.

This page (NASDAQ:VNDA) was last updated on 1/30/2023 by MarketBeat.com Staff